Drug Database
CA

caffeine citrate (Cafnea)

✓ Approved

Phebra · 小分子 · 小分子

什么是 caffeine citrate?

caffeine citrate 是一种小分子,由Phebra研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Oral (PO)。

药物档案

商品名Cafnea
公司Phebra
药物类别小分子
给药途径Injectable (Others), Oral (PO)
状态Approved

治疗适应症

caffeine citrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersApnoea✓ Approved

相关研究文献

PubMedCancer & metabolism2026-11-19

Salidroside decreases lipid abundance, mitochondrial function, and expression of the mitochondrial citrate transporter SLC25A1 via miR-1343-3p in gastric cancer.

Cao Mingyuan M, Zhang Zhendong Z, Du Yuxin Y, Fang Jin J et al.

To investigate the potential mechanisms by which salidroside regulates mitochondrial function, SLC25A1 expression, and lipid abundance in gastric cancer (GC) cells via miR-1343-3p. Transcriptome sequencing was performed on MGC-803 cells before and after salidroside treatment to identify differentially expressed miRNAs and mRNAs. Bioinformatic analysis was then used to screen for candidate molecules. The interaction between miR-1343-3p and SLC25A1 was validated by dual-luciferase reporter assay, sequence alignment, and RNA immunoprecipitation (RIP). Mitochondrial morphology and function were examined by transmission electron microscopy and fluorescent probes. MGC-803 and AGS cells were used to assess the effects of salidroside, miR-1343-3p modulation, and SLC25A1 silencing on mitochondrial citrate export, lipid abundance, and cell proliferation. Furthermore, a nude mouse xenograft model was established to evaluate the effects of salidroside and a miR-1343-3p agomir on tumor growth, the expression of miR-1343-3p and SLC25A1, and tumor metabolic status. Transcriptome sequencing revealed 44 differentially expressed miRNAs and 1,384 differentially expressed mRNAs in MGC-803 cells following salidroside treatment. Among them, miR-1343-3p was significantly upregulated as a tumor-suppressive miRNA, while SLC25A1, a mitochondrial citrate transporter, was significantly downregulated. RT-qPCR and Western blot results demonstrated that salidroside significantly increased the expression of miR-1343-3p while decreasing the mRNA and protein expression of SLC25A1. Dual-luciferase reporter, sequence alignment, and RIP assays confirmed that miR-1343-3p directly targets SLC25A1. Further studies showed that salidroside treatment, miR-1343-3p overexpression, and SLC25A1 silencing could all cause the accumulation of mitochondrial citrate, reduced mitochondrial membrane potential, increased ROS production, and decreased the levels of NADH, ATP, acetyl-CoA, free fatty acids, cholesterol, and triglycerides, while significantly inhibiting GC cell proliferation. However, after knocking down miR-1343-3p, the opposite results were observed, which were efficiently rescued by salidroside. In vivo, both salidroside treatment and the miR-1343-3p agomir administration significantly reduced tumor volume and weight. Tumor tissues from these groups showed increased miR-1343-3p expression, decreased SLC25A1 expression, and lipid metabolic changes consistent with those observed in vitro. Salidroside inhibits GC cell proliferation and tumor growth by upregulating the tumor-suppressive miR-1343-3p, which directly targets and downregulates the mitochondrial citrate transporter SLC25A1. Meanwhile, decreased mitochondrial citrate export, impaired mitochondrial function, and reduced lipid abundance are observed. These findings indicate that miR-1343-3p and SLC25A1 may be promising therapeutic targets for metabolic intervention in gastric cancer.

PMID 43053216
阅读全文 →
PubMedJournal of translational medicine2026-11-19

Metabolic remodeling in early- and late-onset colorectal cancer supports an age-informed detection model.

Wang Ruowei R, Wang Weifeng W, Liao Leen L, Zheng Muxu M et al.

The incidence of early-onset colorectal cancer (EOCRC) has increased in recent decades; however, most metabolomic studies have focused on all age groups. Consequently, it remains uncertain how metabolic alterations drive EOCRC progression and whether biomarker signatures identified in older patients are valid in younger populations. We performed untargeted plasma metabolomic profiling of 791 participants, including those with colorectal cancer (CRC), colorectal adenoma (CRA), and healthy controls. Individuals were stratified by age (<50 and ≥50 years) to explore metabolic remodeling during EOCRC and late-onset CRC (LOCRC) development. A multistep feature selection process and 12 machine learning algorithms were used to establish an age-informed CRC detection model. CRC progression was associated with the suppression of caffeine and histidine metabolism and the enhancement of amino acid metabolism, particularly branched-chain amino acid, glycine-serine, and arginine-proline pathways. EOCRC showed increased phenylalanine, butanoate, and lipoic acid metabolism, whereas LOCRC was enriched in purine and fatty acid biosynthesis. A 7-metabolite panel (caffeine, ergothioneine, hypoxanthine 1, L-valyl-L-alanine, L-seryl-L-aspartic acid, cholic acid, and cycloleucine) was trained and achieved excellent detection values in all age groups (AUC > 0.95). SHapley Additive exPlanations (SHAP) analysis highlighted metabolite-specific contributions, supporting biological interpretability. These findings delineate age-related metabolic remodeling in CRC and demonstrate that integrating plasma metabolomics with machine learning supports a robust and interpretable non-invasive detection approach. The proposed age-informed model may inform future age-tailored CRC detection strategies amid the increasing burden of early-onset cancers.

PMID 43053157
阅读全文 →
PubMedInternational journal of MCH and AIDS2026-11-18

Maternal Caffeine Intake on Fetal and Childhood Outcomes: A Systematic Review.

Rovner Devorah D, Wagner Emily E, Purohit Ishani I, Covelli Alexa A et al.

Maternal caffeine consumption during pregnancy may increase fetal exposure due to reduced caffeine metabolism in high-estrogen states. This review aimed to assess the current literature on maternal caffeine intake and its effects on birth outcomes and fetal development. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed and Web of Science were searched using Boolean keyword strategies related to caffeine exposure during pregnancy and fetal outcomes. Eligible designs included randomized controlled trials, cohort studies, observational studies, cross-sectional studies, and case-control studies. Studies that did not assess caffeine exposure during pregnancy, non-original studies, case reports, animal studies, and those outside the 2015-2025 timeframe were excluded. Two independent reviewers evaluated titles, abstracts, and full texts against predefined eligibility criteria, and disagreements were resolved by a third author. Risk of bias was assessed. We identified 519 records; 17 studies were included after screening. Included cohort and observational designs examined associations between maternal caffeine intake and fetal, neonatal, and childhood outcomes. Several reported dose-dependent associations between higher caffeine intake and reduced fetal growth measures, including lower birth weight and increased risk of small for gestational age, while others found no significant associations after adjusting for confounders. Prenatal caffeine exposure can alter fetal growth and developmental trajectories, but the impact and reliability of results remain questionable. Discrepancies likely stem from confounding maternal lifestyle factors, variations in caffeine sources, exposure timing, intake quantification, populations, and self-reporting biases, underscoring the need for standardized parameters across prospective studies. From a global health perspective, the overall impact of prenatal caffeine exposure remains unclear due to this inconsistent and confounded evidence base. Ongoing research is essential to better define risks and inform consistent, evidence-based public health recommendations across diverse populations.

PMID 43048728
阅读全文 →
PubMedFrontiers in physiology2026-11-18

Caffeine as a context-dependent metabolic, perceptual, and recovery modulator in exercise: implications for substrate utilization, performance, and individual responsiveness.

Liang Zeyu Z, Wang Shan S, Wang Jiuyuan J, Chen Jingfeng J et al.

Caffeine is a widely studied ergogenic aid in sport and exercise science, yet its effects on exercise metabolism, performance, and recovery remain context dependent. Although caffeine is commonly used to enhance alertness, reduce perceived exertion, and improve exercise capacity, its effects vary with dose, ingestion timing, delivery form, exercise modality, habitual caffeine intake, training status, sex-related factors, genotype, and sleep vulnerability. This narrative review provides an evidence-calibrated synthesis of caffeine's central, metabolic, perceptual, performance-related, and recovery-related effects, emphasizing substrate utilization and individual responsiveness. It distinguishes relatively well-supported mechanisms from conditional or inconsistent effects, examines major sources of heterogeneity across studies, and evaluates acute ergogenic benefits alongside potential recovery costs. Evidence indicates that caffeine's most consistent mechanisms involve adenosine receptor antagonism, increased central nervous system activation, and reduced perception of effort or fatigue. Peripheral and metabolic mechanisms, including catecholamine-mediated substrate mobilization, changes in fat oxidation, calcium handling, and glycogen-related responses, are biologically plausible but appear more conditional and protocol dependent. Importantly, caffeine-induced increases in fat oxidation should not be interpreted as direct evidence of glycogen sparing or performance enhancement, because their practical relevance depends on exercise intensity, duration, carbohydrate availability, and the performance outcome assessed. Caffeine shows the strongest ergogenic evidence in endurance exercise, while effects on strength, power, repeated sprint ability, and sport-specific skills are smaller and more variable. Recovery-related applications require particular caution: caffeine may support perceived readiness or selected glycogen-related outcomes when combined with carbohydrate in short-turnaround contexts, but late-day ingestion may impair sleep and thereby compromise broader recovery. Overall, caffeine should be understood as a context-dependent metabolic and perceptual modulator rather than a universally ergogenic supplement. Applied use should prioritize the lowest effective dose, individualized timing, sport-specific trialling, adverse-effect monitoring, and careful consideration of recovery costs. Future research should integrate metabolic markers, performance outcomes, sleep, and individual moderators within ecologically valid sport protocols to clarify when caffeine is beneficial, neutral, or potentially counterproductive.

PMID 43047655
阅读全文 →
PubMedACS pharmacology & translational science2026-11-18

The Ergogenic Effect of Caffeine in Rodents: A Systematic Review and Meta-Analysis, with a Narrative Synthesis of Adenosine A2A Receptor Mechanisms.

de Souza Santos Naiara N, Fabro Izabel Feltrin IF, Carminati Dos Santos Beatriz B, Pereira Débora Maria Russiano DMR et al.

Caffeine is a widely consumed ergogenic aid and a nonselective antagonist of adenosine receptors, including the facilitatory A2A subtype (A2AR), yet the magnitude of its performance-enhancing effect in rodents has not been formally quantified. We conducted a systematic review and meta-analysis of rodent studies administering caffeine before exercise, with risk of bias assessed using the SYRCLE tool (PROSPERO CRD420250653223). Fourteen studies met the eligibility criteria. Six studies of a single systemic dose preceding an aerobic task, comprising 71 animals were pooled using a restricted maximum likelihood random-effects model with a Hartung-Knapp interval, yielding a large ergogenic estimate with wide uncertainty (Hedges' g = +1.31; 95% CI + 0.29 to +2.32; I2 = 71%). Prespecified rules, applied independently of the observed effects, precluded pooling of the two anaerobic studies, which measured different performance constructs, and of the three chronic-exposure studies, whose dosing regimens and exercise modalities were not comparable; these are reported descriptively, as are the intracerebral administration experiments. Risk of bias was frequently unclear or high in the randomization and blinding domains. Receptor-level evidence is reported separately as a narrative synthesis, because the search was not constructed to retrieve mechanistic studies: the ergogenic response was abolished in global and forebrain A2AR-knockout mice and reproduced by the selective antagonist SCH 58261, whereas A2AR agonism with NECA was ergolytic and reversed by caffeine, and deletion of CD73, which depletes the extracellular adenosine pool preferentially supplying A2AR, recapitulated the ergogenic phenotype. The rodent evidence provides preclinical support for A2AR involvement in exercise-induced fatigue on an evidence base too small and too heterogeneous to support therapeutic or performance translation.

PMID 43048230
阅读全文 →
PubMedCompendium of continuing education in dentistry (Jamesburg, N.J. : 1995)2026-11-18

Stannous Fluoride Deposition Into Plaque Biofilm: Effects of Formulation Chemistry and Hops β-Acids Extract Dispersion.

St John Samuel S, Strand Ross R

To evaluate how surfactant-mediated biofilm disruption by hops beta (β)-acids extract influences stannous fluoride (SnF2) penetration and interaction with extracellular metabolites, including lipopolysaccharide (LPS). In two studies, oral biofilms were formed in vivo on artificial enamel surfaces mounted in dental appliances worn by volunteers and subsequently treated ex vivo under controlled conditions. Across the studies, biofilms were treated with supernatants of various commercial 0.454% SnF2 dentifrices containing: (1) pyrophosphate; (2) potassium nitrate (KNO3) and pyrophosphate; (3) tripolyphosphate; and (4) gluconate/citrate-stabilized 0.454% SnF2 (Crest) with and without hops β-acids extract (Activ Bio-Cleanser™). Both studies used phosphate-buffered saline as a negative control (NC). Confocal laser scanning microscopy with component-specific fluorescent probes was used to quantify Sn and LPS distribution relative to bacterial biomass, biofilm thickness, and extracellular polymeric substance (EPS) structure. Image analysis was used to quantify Sn and LPS signal within bacterial regions, normalized to bacterial volume or area; statistical comparisons were made across conditions. SnF2 uptake and penetration varied significantly across formulations. In study 1, the rank order from greatest to least for Sn deposition and LPS neutralization was: gluconate/citrate > KNO3 + pyro > pyro > NC (P < 0.05 between groups). In study 2, the rank order from greatest to least was: gluconate/citrate + hops > gluconate/citrate > tripolyphosphate and KNO3 + pyro > NC (P < 0.05 between groups). Some stabilized SnF2 systems exhibited limited penetration, consistent with diffusion barriers imposed by dense EPS matrices or over-stabilization reducing bioavailability. Gluconate/ citrate-stabilized SnF2-only treated biofilms showed higher deposition per unit bacteria than other SnF2 technologies but uniformly exhibited the majority of uptake in surface regions. In the formulation containing both hops and SnF2, increased Sn penetration and reduced detectable biofilm-associated LPS was observed, consistent with enhanced access of SnF2 to extracellular plaque components following surfactant-enabled biofilm modification. In this case, Sn penetration achieved high relative deposition per unit bacteria in the treated regions throughout the biofilm. Hops β-acids extract acts as a co-surfactant in toothpaste, capable of modifying EPS structure to improve accessibility and interaction of SnF2 with extracellular metabolites within oral biofilms. The observed changes in Sn penetration and biofilm-associated, extracellular LPS are consistent with enhanced cleaning with reduced concentration of known tissue irritants. These findings provide a mechanistic rationale for formulation strategies that enhance SnF2 accessibility within adherent oral biofilms through surfactant-based modification of EPS supporting more efficient biofilm management during oral hygiene and providing a basis for selecting toothpastes based on their efficacy.

PMID 43051125
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多caffeine citrate